PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures
Phase 2
Completed
- Conditions
- Pain
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2006-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT00143442
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- Ejaculation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT00143117
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT00141297
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธAbramson Cancer Center Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
Phase 2
Completed
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00141128
- Locations
- ๐ฉ๐ฐ
Pfizer Investigational Site, Glostrup, Denmark
CP-481,715 Nickel Allergy Study.
Phase 1
Completed
- Conditions
- Dermatitis, Allergic Contact
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00141180
- Locations
- ๐ฉ๐ฐ
Pfizer Investigational Site, Hellerup, Denmark
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Phase 2
Completed
- Conditions
- Impotence
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00141349
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 455
- Registration Number
- NCT00141388
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Montreal, Quebec, Canada
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1561
- Registration Number
- NCT00141193
- Locations
- ๐บ๐พ
Pfizer Investigational Site, Montevideo, Uruguay
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
Phase 3
Completed
- Conditions
- Neuropathic Pain
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 132
- Registration Number
- NCT00141375
- Locations
- ๐ฆ๐บ
Pfizer Investigational Site, NSW, Australia
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00141401
ยฉ Copyright 2025. All Rights Reserved by MedPath